Targeting ganglioneuromas with mTOR inhibitors

We recently identified activated protein kinase B (PKB/AKT) as a tumorigenic driver in childhood ganglioneuroma. Inhibition of the mechanistic target of rapamycin (mTOR), a serine/threonine kinase downstream of AKT, effectively reduced the tumor burden in zebrafish with ganglioneuroma. We propose a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Ting, Shi, Hui, Durbin, Adam D., Look, A. Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Author’s Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849689/
https://www.ncbi.nlm.nih.gov/pubmed/33553609
http://dx.doi.org/10.1080/23723556.2020.1856621
_version_ 1783645347605643264
author Tao, Ting
Shi, Hui
Durbin, Adam D.
Look, A. Thomas
author_facet Tao, Ting
Shi, Hui
Durbin, Adam D.
Look, A. Thomas
author_sort Tao, Ting
collection PubMed
description We recently identified activated protein kinase B (PKB/AKT) as a tumorigenic driver in childhood ganglioneuroma. Inhibition of the mechanistic target of rapamycin (mTOR), a serine/threonine kinase downstream of AKT, effectively reduced the tumor burden in zebrafish with ganglioneuroma. We propose a clinical trial of mTOR inhibitors as a means to shrink large ganglioneuromas prior to surgical resection.
format Online
Article
Text
id pubmed-7849689
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-78496892021-02-05 Targeting ganglioneuromas with mTOR inhibitors Tao, Ting Shi, Hui Durbin, Adam D. Look, A. Thomas Mol Cell Oncol Author’s Views We recently identified activated protein kinase B (PKB/AKT) as a tumorigenic driver in childhood ganglioneuroma. Inhibition of the mechanistic target of rapamycin (mTOR), a serine/threonine kinase downstream of AKT, effectively reduced the tumor burden in zebrafish with ganglioneuroma. We propose a clinical trial of mTOR inhibitors as a means to shrink large ganglioneuromas prior to surgical resection. Taylor & Francis 2021-01-10 /pmc/articles/PMC7849689/ /pubmed/33553609 http://dx.doi.org/10.1080/23723556.2020.1856621 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author’s Views
Tao, Ting
Shi, Hui
Durbin, Adam D.
Look, A. Thomas
Targeting ganglioneuromas with mTOR inhibitors
title Targeting ganglioneuromas with mTOR inhibitors
title_full Targeting ganglioneuromas with mTOR inhibitors
title_fullStr Targeting ganglioneuromas with mTOR inhibitors
title_full_unstemmed Targeting ganglioneuromas with mTOR inhibitors
title_short Targeting ganglioneuromas with mTOR inhibitors
title_sort targeting ganglioneuromas with mtor inhibitors
topic Author’s Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849689/
https://www.ncbi.nlm.nih.gov/pubmed/33553609
http://dx.doi.org/10.1080/23723556.2020.1856621
work_keys_str_mv AT taoting targetingganglioneuromaswithmtorinhibitors
AT shihui targetingganglioneuromaswithmtorinhibitors
AT durbinadamd targetingganglioneuromaswithmtorinhibitors
AT lookathomas targetingganglioneuromaswithmtorinhibitors

Ejemplares similares